Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Perseus Proteomics's Other Operating Expense for the
six
months ended in Mar. 2026 was 円403.9 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was 円550.3 Mil.
Perseus Proteomics's quarterly Other Operating Expense
declined
from Mar. 2025 (円461.0 Mil) to Sep. 2025 (円146.4 Mil) but then
increased
from Sep. 2025 (円146.4 Mil) to Mar. 2026 (円403.9 Mil).
Perseus Proteomics's annual Other Operating Expense
declined
from Mar. 2024 (円982.4 Mil) to Mar. 2025 (円930.5 Mil) and
declined
from Mar. 2025 (円930.5 Mil) to Mar. 2026 (円861.1 Mil).
Perseus Proteomics Other Operating Expense Related Terms
Perseus Proteomics Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Perseus Proteomics's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円550.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of 円550.3 Mil mean?
Perseus Proteomics (TSE:4882) has a Other Operating Expense of 円550.3 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Perseus Proteomics and its competitors.
Is Perseus Proteomics' Other Operating Expense too high?
Perseus Proteomics' current Other Operating Expense is 円550.3 Mil. Overall, Perseus Proteomics has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Perseus Proteomics' Other Operating Expense compare to LLY and JNJ?
Perseus Proteomics' Other Operating Expense of 円550.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Perseus Proteomics and its competitors. Perseus Proteomics's current Other Operating Expense is 円550.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perseus Proteomics stock overvalued right now?
Based on GuruFocus' analysis, Perseus Proteomics (TSE:4882) is currently considered Significantly Undervalued. The stock's GF Value™ is 円441.10, compared to a current price of 円143.00 — trading 67.6% below its estimated fair value. The current Other Operating Expense is 円550.3 Mil. Perseus Proteomics' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Perseus Proteomics (TSE:4882), the current Other Operating Expense is 円550.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perseus Proteomics (TSE:4882) Overvalued in 2026?
Based on GuruFocus' analysis, Perseus Proteomics stock appears to be undervalued.
The current stock price of 円143.00 is trading 67.6% below its estimated GF Value™ of 円441.10.
GuruFocus considers Perseus Proteomics to be Significantly Undervalued.
Key valuation signals for TSE:4882:
Other Operating Expense: 円550.3 Mil
GF Value™: 円441.10 vs. price of 円143.00 (67.6% below fair value)
No single metric tells the full story. See the TSE:4882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody-based therapeutics and diagnostic drugs to cure cancer and other diseases. The Company operates in a single segment, the pharmaceutical business.
60GF Score
Get the complete analysis for TSE:4882
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4882 has been successfully added to your 
